For the quarter ended December 2025, Catalyst Pharmaceutical (CPRX) reported revenue of $152.61 million, up 7.6% over the same period last year. EPS came in at $0.68, compared to $0.70 in the year-ago quarter.
The reported revenue represents a surprise of +9% over the Zacks Consensus Estimate of $140.02 million. With the consensus EPS estimate being $0.42, the EPS surprise was +60.95%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Catalyst performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product revenue,net: $152.5 million compared to the $140.01 million average estimate based on four analysts. The reported number represents a change of +7.5% year over year.
- Revenues- Product revenue, Net- FIRDAPSE: $97.62 million versus $96.43 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +18.3% change.
- Revenues- Product revenue, Net- AGAMREE: $35.3 million versus the four-analyst average estimate of $31.3 million. The reported number represents a year-over-year change of +67.5%.
- Revenues- Product revenue, Net- FYCOMPA: $19.58 million compared to the $12.28 million average estimate based on four analysts. The reported number represents a change of -48.8% year over year.
- Revenues- License and other: $0.11 million versus $0.03 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +909.1% change.
View all Key Company Metrics for Catalyst here>>>
Shares of Catalyst have returned +2.7% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Catalyst Pharmaceuticals, Inc. (CPRX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
